HC Wainwright Issues Pessimistic Forecast for GLSI Earnings

Greenwich LifeSciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Research analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Greenwich LifeSciences in a research note issued to investors on Wednesday, November 18th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($1.46) per share for the year, down from their prior estimate of ($1.29). HC Wainwright currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Greenwich LifeSciences' current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Greenwich LifeSciences' Q4 2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.37) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.36) EPS, Q4 2027 earnings at ($0.36) EPS and FY2027 earnings at ($1.46) EPS.

Separately, Weiss Ratings raised Greenwich LifeSciences from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Greenwich LifeSciences has a consensus rating of "Hold" and a consensus price target of $70.00.

Check Out Our Latest Research Report on Greenwich LifeSciences

Greenwich LifeSciences Price Performance

Shares of NASDAQ:GLSI opened at $19.79 on Friday. The stock's 50-day moving average is $16.78 and its 200 day moving average is $20.82. The company has a market cap of $290.52 million, a PE ratio of 0.00 and a beta of 1.57. Greenwich LifeSciences has a 1 year low of $7.78 and a 1 year high of $34.10.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.06).

Institutional Investors Weigh In On Greenwich LifeSciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Ancora Advisors LLC increased its holdings in Greenwich LifeSciences by 101.2% in the 3rd quarter. Ancora Advisors LLC now owns 21,610 shares of the company's stock worth $390,000 after acquiring an additional 10,870 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Greenwich LifeSciences by 44.4% during the 3rd quarter. Goldman Sachs Group Inc. now owns 56,793 shares of the company's stock valued at $1,025,000 after buying an additional 17,464 shares in the last quarter. BlackRock Inc. bought a new position in Greenwich LifeSciences in the 2nd quarter worth $11,398,000. Deutsche Bank AG purchased a new stake in Greenwich LifeSciences in the 2nd quarter worth $126,000. Finally, Bank of New York Mellon Corp bought a new stake in Greenwich LifeSciences during the second quarter valued at about $1,124,000. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Greenwich LifeSciences

Here are a few of the latest stories about GLSI:

  • Positive Sentiment: HC Wainwright raised its price target to $70 from $69 and kept its Buy rating, signaling continued confidence despite the forecast reductions. Greenwich LifeSciences stock gets price target boost from HC Wainwright
  • Neutral Sentiment: Noble Financial issued forecasts for losses of $1.49 per share in FY2026 and $2.14 in FY2027. These are new estimates rather than reported results or announced changes to its prior forecasts.
  • Negative Sentiment: HC Wainwright lowered its EPS forecasts across late 2026 and 2027. Its FY2026 estimate moved to a loss of $1.46 per share from $1.29, while its FY2027 forecast fell to a loss of $1.46 from $1.17. The wider expected losses are the clearest near-term negative in the updates.

Greenwich LifeSciences Company Profile

(Get Free Report)

Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to reduce the risk of breast cancer recurrence. The company's work centers on GP2, an investigational peptide-based vaccine designed for patients with HER2/neu-positive breast cancer who have completed standard treatment. GP2 is intended to stimulate an immune response against cancer cells expressing HER2/neu and is administered with the immune-system stimulant GM-CSF. Greenwich LifeSciences is evaluating the candidate in clinical trials; it does not have an approved commercial product.

See Also

Earnings History and Estimates for Greenwich LifeSciences (NASDAQ:GLSI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Greenwich LifeSciences Right Now?

Before you consider Greenwich LifeSciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.

While Greenwich LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines